• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Smith Brandon D

    12/26/23 4:32:40 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMPL alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Smith Brandon D

    (Last) (First) (Middle)
    C/O IMPEL PHARMACEUTICALS INC.
    201 ELLIOTT AVENUE WEST, SUITE 260

    (Street)
    SEATTLE WA 98119

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    12/18/2023
    3. Issuer Name and Ticker or Trading Symbol
    IMPEL PHARMACEUTICALS INC [ IMPL ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Restructuring Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Brandon D. Smith 12/26/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $IMPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMPL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMPL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Impel Pharmaceuticals Inc.

      EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/16/24 12:15:09 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:21:28 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:19:30 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen initiated coverage on Impel NeuroPharma with a new price target

      Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00

      5/18/21 7:57:51 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Impel NeuroPharma with a new price target

      Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Impel NeuroPharma with a new price target

      Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/13/21 2:21:35 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/7/21 1:04:43 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care